Results 21 to 30 of about 15,288 (159)

Intratumoral steroidogenesis in castration-resistant prostate cancer: a target for therapy

Prostate International, 2014
Development of castration-resistant prostate cancer (CRPC) in a low androgen environment, arising from androgen deprivation therapy (ADT), is a major problem in patients with advanced prostate cancer (PCa).
Inna Armandari, Agus Rizal Hamid, Gerald Verhaegh, Jack Schalken   +3 more
doaj   +1 more source

A critical assessment framework to identify, quantify and interpret the sources of uncertainty in cost-effectiveness analyses

BMC Health Services Research, 2022
Background Using a standardized approach to describe the sources of uncertainty in cost-effectiveness analyses might bring added value to the local critical assessment procedure of reimbursement submissions in Hungary.
Gergő Merész, Veronika Dóczy, Áron Hölgyesi, Gergely Németh   +3 more
doaj   +1 more source

Circulating Tumour DNA as a Biomarker Source in Metastatic Prostate Cancer

Société Internationale d’Urologie Journal, 2020
Tumour molecular features are increasingly linked to treatment response and patient prognosis in advanced prostate cancer. Plasma cell-free circulating tumour DNA (ctDNA) isolated from a minimally invasive blood draw offers a convenient source of tumour ...
Gillian Vandekerkhove, Alexander Wyatt
doaj   +1 more source

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

Molecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan, Veronika M Metzler, Simone de Brot, Corinne L Woodcock, Anna E Harris, Jennifer Lothion‐Roy, Emeli M Nilsson, Atara Ntekim, Michael S Toss, Jenny L Persson, Francesca Khani, Brian D Robinson, Lorraine J Gudas, Emad Rakha, David M Heery, Catrin S Rutland, Nigel P Mongan   +16 more
wiley   +1 more source

Hijacking emergency granulopoiesis: Neutrophil ontogeny and reprogramming in cancer

Molecular Oncology, EarlyView.
Neutrophils are highly plastic innate immune cells; their functions in cancer extend beyond the tumour microenvironment. This Review summarises current understanding of neutrophil maturation and heterogeneity and highlights tumour‐induced granulopoiesis as a systemic programme that expands immature, immunosuppressive neutrophils via tumour‐derived ...
Gabriela Marinescu, Yi Feng
wiley   +1 more source

Cancer Cell‐Intrinsic Cholesterol Induces Lipid‐Associated Macrophage Differentiation via SP1 Palmitoylation to Promote Prostate Cancer Progression

Advanced Science, EarlyView.
Cancer cell‐intrinsic cholesterol promotes the S‐palmitoylation of SP1, increasing its nuclear translocation and driving the transcription and secretion of MDK, which in turn facilitates the differentiation of macrophages into a lipid‐associated phenotype.
Shirong Peng, Weilong Lin, Zean Li, Ruilin Zhuang, Shengmeng Peng, Bingheng Li, Bingliang Chen, Yong Luo, Yuan Ou, Wei Zhuang, Tao Du, Kaiwen Li, Hai Huang   +12 more
wiley   +1 more source

B4GALNT4‐Mediated Glycosylation of PDK1 Activates the PI3K‐AKT Signaling Pathway to Promote Prostate Cancer Progression

Advanced Science, EarlyView.
This study identifies B4GALNT4 as a key driver of prostate cancer (PCa). It shows that B4GALNT4 glycosylates PDK1 protein at the N531 site, which stabilizes the PDK1 and constitutively activates the PI3K‐AKT pathway. This mechanism promotes tumor cell proliferation, migration, and invasion. The findings establish the B4GALNT4‐PDK1 glycosylation axis as
Shaoqin Jiang, Mengqiang Li, Qingfu Su, Ruiling Dou, Shaoshan Lin, Jili Zhang, Xiaochen Sun, Haolan Yu, Wei Bao, Min Qu, Yan Wang, Chenghua Yang, Xu Gao   +12 more
wiley   +1 more source

Short-term efficacy of enzalutamide in treatment of patients with abiraterone-resistant metastatic castration-resistant prostate cancer [PDF]

精准医学杂志
Objective To investigate the short-term efficacy and safety of enzalutamide in the treatment of patients with abiraterone-resistant metastatic castration-resistant prostate cancer (mCRPC).
MEI Jingchang, SU Xiaonan, YAO Yu, GUAN Fengju, ZHANG Guiming
doaj   +1 more source

Phase Separation of NFIB Suppresses SLC3A2‐Mediated Ferroptosis in Castration‐Resistant Prostate Cancer

Advanced Science, EarlyView.
Castration‐resistant prostate cancer (CRPC) remains sensitive to ferroptosis, but its intrinsic resistance is poorly understood. Here, we identify NFIB as a master suppressor. SIRT7‐mediated NFIB acetylation drives its liquid–liquid phase separation, which promotes SLC3A2 transcription to inhibit ferroptosis.
Qiunuo Li, Danyang Chen, Yongzhen Xia, Yili Long, Nan Huang, Rongna Li, Mengting Shi, Mairehaba Kadier, Huafeng Luo, Xiaohui Chen, Hao Liu, Guanmin Jiang   +11 more
wiley   +1 more source